Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1TQXO)

Drug Name

IMP-731 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Lymphocyte activation gene 3 protein (LAG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Relatlimab	DM28AZV	Melanoma	2C30	Approved	[2]
Anti-LAG3	DMJO402	Gastric adenocarcinoma	2B72	Phase 2	[3]
BMS-986016	DMDCHM7	Hematologic tumour	2B33.Y	Phase 1/2	[4]
IMP-321	DM18ZLW	Allergy	4A80-4A85	Phase 1/2	[5]
Favezelimab	DMYAIE2	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[6]
XmAb22841	DMQB3HD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
FS118	DM0QH9K	Advanced cancer	2A00-2F9Z	Phase 1	[8]
RG6139	DMJFM3O	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
ADPT01	DMS6DPF	Breast cancer	2C60-2C65	Phase 1	[10]
IMP-701	DMXSMF9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lymphocyte activation gene 3 protein (LAG3)	TTNVXAW	LAG3_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
2	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.
5	A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11.
6	A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022 Dec;7(6):100639.
7	Clinical pipeline report, company report or official report of Xencor.
8	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
9	Clinical pipeline report, company report or official report of Genentech.
10	Clinical pipeline report, company report or official report of Novartis.